Navigation Links
The Branded Pharmaceutical Association Comments on Hydrocodone
Date:9/28/2007

BIRMINGHAM, Ala., Sept. 28 /PRNewswire/ -- The Branded Pharmaceutical Association (BPA) represents specialty manufacturers, marketers, and distributors of pharmaceutical products. Some members of the BPA produce, market or distribute Legacy Drugs, which are older, well-established and well recognized drugs, with a history of safety and effectiveness of at least 25 years. All of these products are manufactured in FDA licensed and inspected facilities using current Good Manufacturing Practices as required by FDA regulation. The clinical effectiveness and safety of Legacy Drugs is evidenced by the extensive history these products have in a wide variety of clinical settings in a diverse patient population. Some of these products have had the trust of physicians and other health professionals for 50 years or more.

In 2006, over 130 million prescriptions were written for products containing hydrocodone. Yet of the over 200 brands of hydrocodone containing cough-syrups only 7 have approval status. According to the FDA release:

The FDA has received reports of medication errors associated with formulation changes in unapproved hydrocodone products and reports of confusion over the similarity of the names of unapproved products to approved drug products.

The Branded Pharmaceutical Association fully supports those FDA actions that improve safety, however this appears to be an over reaction to a few already identified incidents, which could easily be corrected by action against those specific companies/products. Removal of all Legacy hydrocodone containing cough-syrups would create a shortage in the market, and dramatically increase the price and create monopolistic positions as we have seen with time released guaifenesin.

Considering hydrocodone was initially approved on March 23, 1943 as an anti-tussive, it would seem more prudent for the FDA to use its limited resources assuring that marketed products are correctly labeled and prescribed instead of taking actions which severely disrupt the marketplace and will surely be windfalls to a handful of companies. BPA believes in our schools of medicine and continues to support the idea that physicians are fully capable of determining appropriate doses and types of medications for their patients.

The FDA has correctly acknowledged that some of the drugs produced in the unapproved category are "medically necessary" and/or are generally considered to be safe and effective. The Branded Pharmaceutical Association is constantly working to ensure that those products are allowed to continue on the market to better meet the needs of physicians and patients alike.


'/>"/>
SOURCE The Branded Pharmaceutical Association
Copyright©2007 PR Newswire.
All rights reserved

Related medicine news :

1. Teen drinking fuelled by Alcohol-branded Wares
2. Get that wedding ring on if you want to be branded a responsible parent!
3. Drug Companies May Be Penalize For Overcharging NHS Tax Payers Money on Branded Drugs
4. South Africa Wins landmark case against pharmaceutical giants
5. Pharmaceutical giant offers AIDS related antifungal drug free to 50 countries
6. Pharmaceutical giant offers AIDS related antifungal drug free to 50 countries
7. Setting up a new pharmaceutical industry in India
8. Medicis Pharmaceutical company enters pediatric market
9. Supply of Radiopharmaceuticals Hampered by Attacks
10. Pharmaceutical companies are targeting patients
11. FDA approves Watson Pharmaceuticals Oxytrol patch
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:3/28/2017)... Mateo, CA (PRWEB) , ... ... ... Society (RSS), a non-profit medical society dedicated to advancing the science and ... leveraging data from its RSSearch Patient Registry, a multi-institutional, observational registry established ...
(Date:3/28/2017)... ... ... Alert Sentry Group LLC., a leader in the Personal Emergency Response System industry, introduced ... Plus. These iSAFE products are the most affordable and most advanced medical alert systems ... direct GPS Location and two-way calling with the push of a button on a ...
(Date:3/28/2017)... ... ... WHO: , Dr. Paul Thomas; Dr. Brian Hooker; Dr. Judy Mikovits; Dr. Jennifer ... speak to the press on behalf of over 200 doctors, scientists, and scientific organizations ... , WHERE: , Zenger Room, National Press Club, 529 14th Street NW, 13th ...
(Date:3/28/2017)... ... March 28, 2017 , ... The Radiology Business Management ... begun to serve as its new executive director. Mr. Still was selected through a ... , “Bob, as he is known to our members, has been a part ...
(Date:3/28/2017)... , ... March 28, 2017 , ... ... physicians, Paul Yost, will begin serving as new board chair for Orange County ... Yost will serve the remainder of soon-to-be former chair Mark Refowitz’s term, which ...
Breaking Medicine News(10 mins):
(Date:3/28/2017)... March 28, 2017  CASI Pharmaceuticals, Inc. (Nasdaq: ... addressing cancer and other unmet medical needs, announced ... for Cancer Research annual meeting.  The first poster ... "Evaluation of ENMD-2076 in Combination with Anti-PD1 ... poster to be presented on April 4 is ...
(Date:3/28/2017)... , March 28, 2017 Elysium ... with Cambridge academic ...   The Milner Therapeutics Institute today announces Elysium ... Health has committed significant investment for collaborative projects with academic ... four years. This is the first major research investment outside ...
(Date:3/27/2017)... -- A recent study at Shriners Hospitals for Children – ... country dedicated to the treatment of pediatric burns and ... Surfacide Helios ® UV-C Disinfection System is ... not killed by the EVS (manual) cleaning process alone." ... Association,s 49th Annual Meeting in Boston ...
Breaking Medicine Technology: